NL - ProFibrix closes $11m Series A financing round
ProFibrix BV, a Leiden-based biotech company focused on products to stop bleeding and initiate tissue repair, has closed a Series A financing round raising $11m. The round was led by Index Ventures and backed by some of the current share holders of ProFibrix. It was also announced that Dr. Bram Bout, who previously held the position of VP protein production at Crucell and has approximately 15 years experience in the biopharmaceutical industry, has joined ProFibrix as of 1 April 2007 as chief technology officer.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater